| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Sohn Catherine A. | Director | C/O MAZE THERAPEUTICS, INC., 171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO | /s/ Courtney Phillips, as attorney-in-fact | 08 Jan 2026 | 0001555132 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MAZE | Common Stock | Options Exercise | $25,977 | +2,493 | $10.42 | 2,493 | 06 Jan 2026 | Direct | ||
| transaction | MAZE | Common Stock | Sale | $96,270 | -2,493 | -100% | $38.62 | 0 | 06 Jan 2026 | Direct | F1 |
| transaction | MAZE | Common Stock | Options Exercise | $216,152 | +20,744 | $10.42 | 20,744 | 07 Jan 2026 | Direct | ||
| transaction | MAZE | Common Stock | Options Exercise | $30,166 | +2,895 | +14% | $10.42 | 23,639 | 07 Jan 2026 | Direct | |
| transaction | MAZE | Common Stock | Options Exercise | $34,188 | +3,281 | +14% | $10.42 | 26,920 | 07 Jan 2026 | Direct | |
| transaction | MAZE | Common Stock | Sale | $1,052,785 | -26,920 | -100% | $39.11 | 0 | 07 Jan 2026 | Direct | F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | MAZE | Stock Option (Right to Buy) | Options Exercise | $0 | -2,493 | -44% | $0.000000 | 3,211 | 06 Jan 2026 | Common Stock | 2,493 | $10.42 | Direct | F3 |
| transaction | MAZE | Stock Option (Right to Buy) | Options Exercise | $0 | -20,744 | -100% | $0.000000 | 0 | 07 Jan 2026 | Common Stock | 20,744 | $10.42 | Direct | F4 |
| transaction | MAZE | Stock Option (Right to Buy) | Options Exercise | $0 | -2,895 | -90% | $0.000000 | 316 | 07 Jan 2026 | Common Stock | 2,895 | $10.42 | Direct | F3 |
| transaction | MAZE | Stock Option (Right to Buy) | Options Exercise | $0 | -3,281 | -36% | $0.000000 | 5,805 | 07 Jan 2026 | Common Stock | 3,281 | $10.42 | Direct | F5 |
| Id | Content |
|---|---|
| F1 | The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.61 to $38.6225 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 2 of this Form 4. |
| F2 | The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.04 to $39.85 per share, inclusive. |
| F3 | The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on April 1, 2023, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |
| F4 | The option is fully vested. Pursuant to the terms of the reporting person's award agreement with the Issuer, the award became fully vested on February 2, 2024. |
| F5 | The option vested or vests as to 1/36th of the total award monthly, with the first tranche vested on January 1, 2025, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. |